Lourd Capital’s Novo Nordisk NVO Stock Holding History

Lourd Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,046	Closed	-$323K	–	262
2017 Q4	$323K	Buy	+12,046	New	+$306K	0.02%	218

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Lourd Capital's NVO Position: Q1 2018 in Review

Lourd Capital sold out of Novo Nordisk (NVO) in Q1 2018, closing a stake of 12,046 shares — an estimated $323K sold.

Lourd Capital first reported a position in NVO in Q4 2017 and held it in 1 quarter. The position peaked at $323K in Q4 2017. 553 funds tracked by Wall St. Rank hold NVO as of Q1 2018.

Lourd Capital reported no remaining Novo Nordisk position as of Q1 2018 after selling out during the quarter.
Lourd Capital sold 12,046 Novo Nordisk shares in Q1 2018, an estimated $323K.
Lourd Capital first reported a position in Novo Nordisk in Q4 2017 and held it in 1 quarter.
Lourd Capital's Novo Nordisk position peaked at $323K in Q4 2017.
553 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2018.

Based on Lourd Capital's 13F filing for Q1 2018, filed 10 Apr 2018.